De novo expression of Sialyl-Tn (STn) antigen is one of the most common features of intestinal metaplasia (IM) and gastric carcinomas, and its biosynthesis has been mostly attributed to ST6GalNAc-I activity. However, the regulation of this glycosyltransferase expression is not elucidated. In IM lesions and in the intestine, CDX2 homeobox transcription factor is co-expressed with STn and ST6GalNAc-I. We therefore hypothesized that CDX2 might induce STn expression by positive regulation of ST6GalNAc-I. We showed that ST6GalNAc-I transcript levels and CDX2 have a coordinated expression upon Caco-2 in vitro differentiation, and overexpression of CDX2 in MKN45 gastric cells increases ST6GalNAc-I transcript levels. Nine putative CDX-binding sites in the ST6GalNAc-I-regulatory sequence were identified and analyzed by chromatin immunoprecipitation in Caco-2 cells and in IM. The results showed that CDX2 protein is recruited to all regions, being the most proximal sites preferentially occupied in vivo. Luciferase assays demonstrated that CDX2 is able to transactivate ST6GalNac-I-regulatory region. The induction was stronger for the regions mapped in the neighbourhood of ATG start codon and site-directed mutagenesis of these sites confirmed their importance. In conclusion, we show that CDX2 transcriptionally regulates ST6GalNAc-I gene expression, specifically in the preneoplastic IM lesion.
ST6GalNAc-I is a α2,6-sialyltransferase present in several human tissues. The active enzyme, with a predicted 600 amino-acid length, 1 transfers a sialic acid residue to GalNAcα-O-Ser/Thr, generating sialyl-Tn (STn) antigen. The biosynthesis of STn has been mostly attributed to ST6GalNAc-I activity, both in vitro and in vivo. [1] [2] [3] [4] It is rarely observed in normal tissues but frequently accompanies cancer progression, being one of the most common features of premalignant lesions of the gastrointestinal tract, namely intestinal metaplasia (IM), 5, 6 and of carcinomas, namely gastric carcinomas. [5] [6] [7] However, to date, little is known about ST6GalNAc-I regulation that might explain aberrant expression of STn in preneoplastic and cancer.
Previous studies identified the homeobox transcription factor CDX2 as a direct regulator of MUC2 mucin expression, 8, 9 the major carrier of STn in IM, in most gastric carcinomas 10 and in gastrointestinal mucinous adenocarcinomas. 11 Under normal conditions, CDX2 expression in adults is restricted to the intestine, being considered a 'master regulator' of intestinal terminal differentiation. However, CDX2 becomes ectopically expressed in human IM lesions of the stomach, 12,13 oesophagus 14 and gallbladder. 15 Both in the intestine and in IM foci in the stomach, CDX2 is coexpressed with MUC2, 12 ST6GalNAc-I 4 and STn. 5, 6 Besides MUC2, CDX2 controls the expression of multiple other intestinal proteins, such as LI-cadherin (LI-cad), 16 sucrase-isomaltase (SI) 17 and CDX2 itself. 18 A chromatin immunoprecipitation (ChIP)-seq analysis performed in the human intestinal cell line Caco-2 has further revealed direct binding of CDX2 to novel target genes and binding sites, namely to a 3′-end enhancer element of the HNF4α gene. 19 Caco-2 in vitro spontaneous differentiation into enterocytelike cells is accompanied by an increase in CDX2 expression, 20 as well as alterations in the cellular glycosylation profile and enzyme expression/activity. [21] [22] [23] [24] [25] [26] Moreover, the genetic regulation of glycosyltransferases-β3Gal-T5 and FUT2-by CDX2 has already been described in the intestinal cell lines. 24, 27 We therefore hypothesized that CDX2 homeobox transcription factor was involved in characteristic glycoproteome modifications of the preneoplastic lesion IM, namely the regulation of the expression of ST6GalNAc-I and its biosynthetic product STn. In order to evaluate the involvement of CDX2 on ST6GalNAc-I gene transactivation, both in vitro and in vivo gastrointestinal models were used.
MATERIALS AND METHODS Human Tissue Samples
Frozen sections of gastric specimens with IM foci adjacent to carcinomas were obtained from patients undergoing surgery at Hospital S. João, Medical Faculty (Porto, Portugal) after ethical committee's approval and informed consent of the patients. Serial sections were cut and used for immunostaining.
Collection of samples for ChIP assays was performed in one case of IM under the same ethical approval process as above. Normal gastric mucosa and IM foci were selected upon frozen specimen's microscopic evaluation at the operating theater after removal of gastric cancer specimens.
Immunostaining
Immunohistochemical analysis of frozen sections was performed using anti-human CDX2 (CDX2-88 clone, Biogenex), anti-human MUC2 (PMH1 clone hybridoma supernatant, Copenhagen, Denmark), anti-human ST6GalNAc-I (2C3 clone hybridoma supernatant, Copenhagen, Denmark) and anti-human STn (TKH2 clone hybridoma supernatant, Copenhagen, Denmark). Negative controls were performed by omission of primary antibodies.
Briefly, for CDX2 and MUC2 immunostaining, the avidinbiotin-peroxidase complex (ABC) method was used. Frozen specimens were fixed in cold methanol for 5 min (for CDX2 staining) or acetone for 10 min (for MUC2 staining) and then treated with 3% hydrogen peroxide (H 2 O 2 ) in methanol for 10 min to block endogenous peroxidase. Sections were then incubated for 45 min with normal rabbit serum in phosphate buffered saline (PBS) with 10% bovine serum albumin (BSA) to block nonspecific staining. Normal serum was then replaced by the primary antibodies (CDX2-88 1:50 and PMH1 undiluted hybridoma supernatant) in PBS with 5% BSA. Sections were incubated overnight at 4°C. After washing, sections were incubated with biotin-labeled secondary rabbit anti-mouse antibody (Dako, Glostrup, Denmark) diluted 1:100 in PBS with 5% BSA for 30 min and with ABC Kit (Vector Labs, CA, USA) for 30 min. The reaction was developed with 0.05% 3,3′-diaminobenzidinetetrahydrochloride containing 0.01% H 2 O 2 , and sections were then counterstained with haematoxylin, dehydrated and mounted. Slides were examined using a Zeiss Optical Microscope.
For ST6GalNAc-I and STn immunofluorescence in frozen specimens, sections were fixed in cold acetone for 10 min and incubated for 20 min with normal rabbit serum in PBS with 10% BSA. Normal serum was then replaced by specific primary antibody (2C3 undiluted supernatant and TKH2 1:5) in PBS with 5% BSA. Sections were incubated overnight at 4°C. After washing, sections were incubated with rabbit antimouse Ig FITC-labeled secondary antibody (Dako, Glostrup, Denmark) diluted 1:100 in PBS with 5% BSA for 45 min, protected from light. DAPI was used as a nuclear counterstain, and slides were mounted in Vectashield mounting media (Vector Labs). Samples were examined under a Leica DM2000 fluorescence microscope equipped with DAPI and FITC interference filters. Images were acquired using a Leica DFC340 FX camera and Leica Application Suit software.
Cell Culture
Human gastric carcinoma cell lines AGS (obtained from ATCC) and MKN45 (obtained from the Japanese Collection of Research Bioresources) were grown in RPMI 1640 medium with Glutamax (GIBCO) while human colon carcinoma cell line Caco-2 was maintained in Dulbecco's minimal essential medium (DMEM) (GIBCO). Media were supplemented with 10% inactive fetal bovine serum (FBS) (Invitrogen) and 1% antibiotics (100 U/ml penicillin and 100 μg/ml streptomycin) (GIBCO), and cells were maintained at 37°C in a humidified 5% CO 2 incubator.
Time-Course, CDX2 Overexpression and CDX2 Knockdown Experiments
For the time-course experiments on Caco-2, 1 × 10 5 cells per well were seeded in six-well plates and harvested 2 days before reaching confluence, at confluence (Day 0) and at variable times after confluence.
For CDX2 overexpression in MKN45, cells seeded in sixwell plates and at ≈80% confluence were transfected with 1 μg of a human CDX2 expression vector containing two FLAG tags at the N-terminus 18 or the corresponding empty vector in a ratio of 1:1.5 relatively to Lipofectamine 2000 reagent in Opti-MEM medium (GIBCO).
For CDX2 knockdown in AGS cells, cells seeded in six-well plates and at ≈80% confluence were transfected with a mix of three double-stranded small interfering RNA (siRNA) directed to different sequences of CDX2 mRNA (siCDX2) or scrambled controls in a total concentration of 50 nM. Target sequences and scrambled controls were chosen according to standard RNAi rules. The siRNA duplexes were used in a ratio of 1:5 relatively to Lipofectamine 2000 reagent in Opti-MEM medium. siRNA sequences are shown in Supplementary  Table S1 .
RNA Extraction, Reverse Transcriptase Assay and Quantitative PCR Total RNA was extracted using TRI Reagent (Sigma, St Louis, MO, USA) and reverse transcription was performed with 3.5 μg total RNA. Specific transcripts were amplified using SYBR Green (Applied Biosystems, Foster City, CA, USA) in a fluorescence reader ABI Prism 7500 (Applied Biosystems). The sequences of the primers used are presented in Supplementary  Table S1 . 18S levels were used for normalization of target gene 
ChIP in an Intestinal Cell Line and in Human Intestinal Metaplasia
In vitro ChIP was carried out using 6 days postconfluence Caco-2 cells (Day +6) using Magna ChIP Kit (Upstate Biotechnology, Millipore, Temecula, USA) according to the manufacturer's recommendations. Briefly, cells were washed 1 × with PBS, and DNA/protein crosslinking was induced with 1% formaldehyde for 10 min at room temperature and stopped with glycine. After washing 1 × in PBS containing protease inhibitors, cells were lysed and sonicated in nuclear lysis buffer. The DNA fragment length range after sonication was checked, by running sonicated DNA on a gel. The solubilized chromatin was then incubated with anti-CDX2 antibody (BioGenex, The Hague, The Netherlands) or isotype control immunoglobulin G (IgG) together with Protein G-magnetic beads, overnight at 4°C. Immunoprecipitated chromatin was then washed, and reversion of the crosslink was performed with proteinase K at 45°C for 2 h followed by a 10-min incubation at 95°C. DNA was then purified and analyzed by quantitative PCR using primer pairs covering the human ST6GalNAc-I promoter (Supplementary Table S1 ). For in vivo ChIP, whole surgical specimens were briefly washed with water for removal of blood, and areas adjacent to the carcinoma were collected. The mucosa was separated from the muscle layer and washed in cold PBS, and the tissue segment was then cut into smaller pieces to facilitate the fixation in 1% formaldehyde and fast frozen in liquid nitrogen. Without thawing, the tissue was pulverized using a Biopulverizer (Biospec Products, Bartlesville, USA) to facilitate posterior lysis. Following this step, the Magna ChIP Kit was used as described. An adjacent/contiguous sample was collected for each of the fragment used for ChIP, frozen in OCT and stained with haematoxylin and eosin to check for the presence of IM.
Each experiment was carried out three times (for the Caco-2 cell line) or once (for each of the surgical specimens) in triplicate. The results are expressed as mean ± s.d. of the triplicates from a representative experiment.
Construction of Luciferase Reporter Plasmids
Three overlapping fragments upstream of human ST6GalNAc-I gene (−1.6, − 0.8 and − 0.3 kbp starting from the transcription start site) were amplified by PCR from purified genomic DNA samples obtained from human normal blood using BR1+8, BR4 and BR9 as forward primers (Supplementary Table S1 ) and a reverse primer containing an overhang immediately upstream of the transcription start site (5′-TATAGG TGGTGGGTCGGGTTC-3′). The amplified fragments were analysed on a 1% Tris-borate EDTA (TBE) agarose gel and gelextracted using the QIAquick Gel Extraction Kit (Qiagen). The fragments were then cloned into pTA-Luc, an in housedeveloped luciferase TA-cloning vector. The search for putative transcription factor-binding sites in these regions was performed in TRANSFAC. 28 Reporter plasmids with mutated putative CDX2-binding sites were generated by site-directed mutagenesis (oligos listed in Supplementary Table S1) using the QuickChange protocol (Stratagene, Cedar Creek, USA). Mutations were created by substitution of A/T triplets for C/G triplets not prone to bind CDX2. All the constructed plasmids were verified by sequencing using the Luc-F and Luc-R plasmid primers (Supplementary Table S1 ), to ensure that they had the predicted sequences.
Luciferase Assays
Human gastric carcinoma cell lines AGS and MKN45 were seeded in 24-well plates and cultured under standard conditions. When ≈80% confluent, cells were transfected with a DNA mix in 300 μl of Opti-MEM media (Invitrogen), free of antibiotic and antimycotic, added to each well. In all, 0.5 μg of each reporter plasmid were used for cell transfection with Lipofectamine 2000 (Invitrogen, Carlsbad, USA). Cells were co-transfected with 1 μg of the human CDX2 expression vector or the corresponding empty vector and also of the 0.3 μg Renilla luciferase reporter vector. Ratio used was 1 mg DNA:1.5 ml Lipofectamine. Twenty-four hours posttransfection, Opti-MEM media was replaced by media supplemented with 10% FBS and 1% penicillin-streptomycin, and 48 h after transfection, luciferase activity was measured. Total extracts were prepared using the Dual-Luciferase Reporter Assay System Kit (Promega, Madison, USA) according to the manufacturer's instructions, and luciferase activity was measured in a 1450 Microbeta luminescence counter (Wallac, Perkin Elmer, Massachussets, USA). As controls, we used a luciferase vector with a CMV promoter and a promotorless 
RESULTS

CDX2 Expression is Associated with ST6GalNAc-I and STn Expression in Intestinal Metaplasia
We observed that CDX2, MUC2, ST6GalNAc-I and STn are co-expressed in IM (Figure 1 ) and are absent in normal gastric mucosa, extending previous observations from our group. 4, 12 ST6GalNAc-I mRNA and CDX2 have a Coordinated Expression During in vitro Spontaneous Differentiation of Caco-2 Cells Caco-2 cell line is derived from colon adenocarcinoma and frequently used as a model for intestinal differentiation as it undergoes spontaneous in vitro differentiation into enterocyte-like cells upon confluence. This in vitro differentiation is accompanied by an increase in CDX2 expression, 20 and it was previously shown that CDX2 regulates β3Gal-T5 in this cellular model. 24 Therefore, we chose this cell line to assess the putative regulation of the ST6GalNAc-I gene by CDX2. Consistent with previous observations, CDX2 protein expression progressively increased during Caco-2 differentiation (Figure 2a , as a representative example of a total of three experiments), and ST6GalNAc-I transcript levels showed a concordant increase in time-course experiments (Figure 2b ). The previously identified CDX2 target β3Gal-T5 was used as a control. STn expression was also observed in Caco-2 cells (Supplementary Figure S2) . However, STn expression levels are maintained along Caco-2 culture and do not accompany ST6GalNAc-I and CDX2 increase (data not shown). We could also not explore our previous findings of MUC2 as a carrier of STn, as Caco-2 cells mainly differentiate into enterocytic lineage and consequently express very low levels of MUC2. 29 As activity and protein levels of several glycosyltransferases change during Caco-2 in vitro differentiation, [21] [22] [23] [24] [25] [26] we decided to check whether or not the increase observed for ST6GalNAc-I mRNA expression is restricted or part of a more general glycosyltransferase induction. Therefore, the levels of other relevant glycosyltransferases were also evaluated by quantitative PCR (Supplementary Figure S1A) . We observed that GalNAc-T3 shows an expression profile similar to ST6GalNAc-I. The correspondent increase in the GalNAc-T3 protein expression can be also observed by immunohistochemistry (Supplementary Figure S1B) .
CDX2 Regulates ST6GalNAc-I mRNA Expression in Gastric Carcinoma Cell Lines
In order to assess the putative involvement of CDX2 in ST6GalNAc-I expression regulation in the gastric setting, we overexpressed and downregulated CDX2 in gastric cell lines. Because of its low CDX2 expression levels, MKN45 cell line was transfected with a human CDX2 expression vector (Figure 3a) , and an increase in ST6GalNAc-I mRNA levels was observed 72 h after transfection, whereas the levels of the CDX2 targets β3Gal-T5 and LI-cad start to increase earlier (Figure 3b) . Nevertheless, no increase in STn, the ST6GalNAc-I biological product, could be detected both by immunofluorescence and flow cytometry (data not shown).
Among gastric carcinoma cell lines, AGS expresses high levels of CDX2 and was therefore used as a model of CDX2 downregulation using siRNAs (Figure 3c) . In this experiment, we observed that 48 h after transfection with a mix of siCDX2 there was a decrease of about 50% in ST6GalNAc-I mRNA levels as well as in the CDX2 known targets β3Gal-T5 and LIcad. However, 72 h after transfection, ST6GalNAc-I levels increased again, despite that low levels of CDX2 and other targets are maintained (Figure 3d) . Again, STn expression levels were not altered by CDX2 downregulation (data not shown).
Identification of Active CDX2 cis-Elements within the ST6GalNAc-I Gene-Regulatory Region
The ST6GalNAc-I promoter has not been characterized thus far. As most gene-regulatory regions are located upstream of the start codon, we inspected in silico about 2000 bp upstream of the ST6GalNAc-I translation start site for CDX consensusbinding sequences, using the TRANSFAC database. 8 
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We identified nine putative-binding regions (Figure 4a ), which were analysed by ChIP assay in Caco-2 cells 6 days after confluence. All putative CDX-binding sites were considered except BR3, as no suitable primers could be designed to specifically amplify this region owing to its high A/T content. The results show that CDX2 protein was able to bind to the eight regions studied, when compared with an irrelevant IgG control (Figure 4b ).
CDX2 is Bound to ST6GalNAc-I-Regulatory Region in Human Intestinal Metaplasia
In order to confirm the binding of CDX2 to the ST6GalNAc-I-regulatory region and its relevance in vivo, ChIP was performed against CDX2 in a surgical sample of human IM, where the association between expression of the two molecules had been observed. 4, 12 As CDX2 is present in the stomach exclusively in the foci of IM, a whole mucosa fragment containing both normal and metaplastic glands was used. Again, all putative CDX2-binding sites were considered except BR3. Another set of primers encompassing the CDX-binding site on the SI promoter was used as a positive control (primer sequences in Supplementary  Table S1 ). The results showed that CDX2 was bound to BR7 and BR9 regions, which are located close to the translation start site ( Figure 5 ). As expected, CDX2 was also bound to SI promoter. A fragment of normal gastric mucosa CDX2 regulates ST6GalNAc-I in intestinal metaplasia R Pinto et al was used as a negative control. As CDX2 is not present in the normal stomach, no signal was detected. We further tested a fragment of intestinal mucosa, where CDX2, ST6GalNAc-I
and STn are expressed in the normal setting. ChIP analysis demonstrated for the first time that CDX2 binds to all the considered regions ( Figure 5 ). 
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CDX2 Transactivates ST6GalNAc-I-Regulatory Region in Gastric Carcinoma Cell Lines
After observing that CDX2 binds to all putative CDX-binding sites located upstream of ST6GalNac-I coding sequence both in Caco-2 cells and intestinal mucosa, we assessed whether CDX2 was able to regulate ST6GalNac-I through its promoter region. Three different luciferase reporter plasmids containing 1.6,~0.8 and~0.3 kb genomic fragments upstream of the human ST6GalNAc-I start codon were used for cell transfection and luciferase assays in two gastric carcinoma cell lines, AGS and MKN45, in combination with a CDX2 expression vector or the corresponding control vector. CDX2 promoter was used as a positive control, as it is known that this protein regulates its own promoter. 18 As shown in Figure 6 , CDX2 was able to transactivate all the three ST6GalNAc-I promotertested constructs in both cell lines, the effect being more evident for the MKN45 cell line. A stronger induction was observed for the shorter fragment, suggesting that the most important regulatory sites are mapped in the neighbourhood of the start codon (within the 0.3pST6GalNac-I-Luc construct). We therefore used this smaller fragment to produce a series of mutants where A/T triplets were replaced by C/G triplets, hampering CDX2, to examine the functional role of the three CDX2-binding sites located within the 0.3pST6Gal-Nac-I-Luc construct. The three most proximal sites (BR5, BR6 and BR7) were mutated independently or together by site-directed mutagenesis, in which two of them (BR5 and BR6) were always mutated together owing to their proximity. The wild-type and the three ST6GalNAc-I mutant constructs were transfected with a human CDX2 expression vector in AGS and MKN45 cells, and the promoter activity was evaluated by luciferase assay. The results ( Figure 6 ) showed that each independent or combined mutation set led to a decrease in promoter activity when compared with the nonmutated fragment, and this decrease is more evident in the MKN45 cell line. Despite that mutation of the three most proximal sites does not completely abrogate the ST6GalNac-Iregulatory region functionality, there is a strong impairment in promoter regulation, namely in the MKN45 cell line, where the transactivation fold of the triple mutant is close to the value for the empty vector (here normalized to 1).
DISCUSSION
In the present study, we have demonstrated the role of an intestine-specific homeoprotein, CDX2, on the transcriptional regulation of ST6GalNAc-I gene. We showed that CDX2 is de novo expressed in IM, 12 together with ST6GalNAc-I glycosyltransferase and its biosynthetic product, STn. In contrast, in adjacent non-metaplastic gastric mucosa, CDX2 and STn are absent, while ST6GalNAc-I is very weakly expressed. 4 The expression of CDX2 and STn has been independently described in IM 5, 12 and in a specific subset of CDX2 regulates ST6GalNAc-I in intestinal metaplasia R Pinto et al carcinomas-the mucinous type. 11, [30] [31] [32] Moreover, previous studies from our group showed that STn is mostly carried by MUC2 mucin in IM, gastric and mucinous carcinomas from several locations. 10, 11 Taken together, these observations support the hypothesis that modulation of STn expression by CDX2 might result from direct transcriptional regulation of ST6GalNAc-I gene.
In favour of this possibility, we found nine TA-rich putative CDX-binding sites within a 2-kb region upstream the ST6GalNAc-I start codon. The human ST6GalNAc-I promoter has not been characterized, and we could not identify a TATA box, which is in agreement with the mouse ST6GalNAc-I gene. 33 Eight out of the nine putative CDXbinding sites found were shown to recruit the transcription factor both in Caco-2 cell line and in intestinal mucosa. The presence of many binding sites for a transcription factor in a gene promoter has been described and is, in fact, an indication of relevance of that transcription factor on the expression regulation of target genes. 34 CDX2 itself is autoregulated and at least six CDX2-binding sites are identified in a 1.2-Kb promoter. 18 However, it cannot be excluded that the binding of CDX2 to all the tested regions could be originated from a 'neighbourhood effect', if the PCR-analysed fragments were too long after DNA sonication. If the analysed fragments contain two putative sites, they will be amplified and generate false positivity even if CDX2 is only bound to one site. However, this hypothesis is not likely as the analysis of the sonicated DNA on a gel showed that most of the fragments were 100-200 bp in length, thus probably containing only one site.
The analysis of overlapping fragments containing a sequence of 1644 bp upstream the human ST6GalNAc-I start codon by luciferase assays, combined with site-directed mutagenesis of putative CDX2-binding sites, further showed that CDX2 is able to transactivate the ST6GalNac-I-regulatory region in gastric cell lines, with the effect being more evident for the MKN45 cell line. It is not surprising that AGS cells do not show a similar effect, because the endogenous levels of CDX2 are higher than in MKN45 cells, possibly saturating the system and thus limiting the effect on ST6GalNac-I transactivation upon CDX2 overexpression. The results also suggested that the most important regulatory sites are mapped in the vicinity of the start codon, as already observed for other genes regulated by CDX2. 18 Nevertheless, the contribution of more distant regulatory regions 19 cannot be discarded to explain ST6GalNAc-I regulation. Also in IM, where regulation of ST6GalNac-I by CDX2 holds strong promise as a biological explanation for STn aberrant expression, we demonstrated the preferential recruitment and activity of CDX2 to sites closer to the translation start site. Mutation of the three most proximal sites almost completely abrogate the ST6GalNac-I-regulatory region functionality in the MKN45 cell line. Taken together, these observations suggest that CDX2 has a role in the modulation of promoter activity, but other transcription factors may cooperate in ST6GalNac-I transactivation. Dynamic cooperation between CDX2 and other partners is not a rare phenomenon and has been demonstrated for other genes. [35] [36] [37] The regulation of glycosyltransferases by CDX2 has been described, 24, 27 in particular the transcriptional control of β3Gal-T5 in the Caco-2 intestinal cell line. 24 This cellular model expresses increasing amounts of CDX2 20 and also alters its glycosylation profile and enzyme expression/activity along enterocytic differentiation, [21] [22] [23] [24] [25] [26] suggesting that CDX2 can act as a regulator of the glycosylation in this cell line. Figure 6 CDX2 transactivates ST6GalNAc-I. Three different luciferase reporter plasmids containing~1.6,~0.8 and~0.3 kb genomic fragments upstream of the human ST6GalNAc-I start codon were tested independently in two gastric carcinoma cell lines, AGS and MKN45, in combination with a human CDX2 expression vector or the corresponding control empty vector. Another set of fragments comprising independent and combined mutations of the most proximal sites (BR5, BR6 and BR7) were also used. The CDX2-putative-binding regions are identified as small bars in the fragments, and the order corresponds to the one shown in Figure 4a . As a control, CDX2 promoter itself was used. The values obtained were corrected for transfection efficiency with Renilla luciferase activity, and results are expressed as fold induction compared with values obtained for the empty vector (here normalized to 1). The results are expressed as mean ± s.d. of at least six values from at least two experiments performed in triplicate for each fragment (*Po0.05 and **Po0.01).
CDX2 regulates ST6GalNAc-I in intestinal metaplasia R Pinto et al
Consistent with this hypothesis, we observed that ST6GalNAc-I transcript levels increase upon Caco-2 spontaneous in vitro differentiation. In addition to ST6GalNAc-I, and the already identified β3Gal-T5, we also observed an increase in GalNAc-T3 transcripts in the Caco-2 cell line. Besides, also in the gastric cancer cell line MKN45 CDX2 showed a clear impact on ST6GalNAc-I regulation. The same impact is not detected in AGS cells upon CDX2 downregulation. In this model, ST6GalNAc-I levels were not consistently decreased over time, leading to the supposition that ST6GalNAc-I regulation is not entirely dependent on CDX2, as described for other CDX2 targets. [35] [36] [37] The dramatic decrease of CDX2 levels 72 h posttransfection might activate compensatory mechanisms by alternative transcription factors acting on ST6GalNAc-I regulation. However, we could not detect an increase in STn expression simultaneously to ST6GalNAc-I transcript levels, when CDX2 was overexpressed in MKN45 for 72 h (data not shown). The incomplete overlap between ST6GalNAc-I mRNA detection and STn might be explained by competition for the GalNAc substrate between ST6GalNAc-I and other glycosyltransferases, such as Core1 Gal-transferase. It is also possible that the kinetics of STn biosynthesis by ST6GalNAc-I is slower and takes more time to show an effect in STn expression. Alternative possibilities for aberrant STn expression in cancer contexts include mutations or promoter methylation of the molecular chaperone Cosmc, 38,39 aberrant localization of glycosyltransferases in the ER/Golgi, 40, 41 or the activity of another sialyltransferase from the same sub-family as ST6GalNAc-I-ST6GalNAc-II 4 -have been demonstrated. This enzyme, ST6GalNAc-II, was also shown to have some specificity in vitro for GalNAc substrates O-linked to proteins (Tn antigen). Moreover, a lack of concordance observed between ST6GalNAc-I and STn expression in gastric carcinomas has been observed in colorectal carcinomas, 42 and it is known that cell lines and tissues lacking STn may still show low levels of ST6GalNAc-I mRNA, 43 indicating that alternative biosynthetic mechanisms may be at play.
Understanding how glycosylation is controlled is indispensable for a better understanding of cancer initiation and progression, as expression of specific O-glycan structures is closely related to cell differentiation. Our study identified a new mechanism of glycosylation control in gastric carcinogenesis by showing that CDX2 has a role in ST6GalNAc-I gene regulation in IM and some cell line models. For the first time, we demonstrated that a single homeobox protein transcriptionally regulates a glycoprotein profile associated with IM and gastric cancer.
